Clinical Trials

84 enrolled

Pancreatic Neoplasms

NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

106 enrolled

Phase 1 Not yet recruiting

Pancreatic cancer, adult

NCT07107750 2026-02-04

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

48 enrolled

Biliary Tract Neoplasms

NCT07383922 2026-02-04

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

524 enrolled

Pancreatic Neoplasms

NCT07369791 2026-01-28

NOBLE

76 enrolled

Advanced Biliary Tract Cancer(BTC)

NCT06855225 2026-01-14

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

29 enrolled

Liver Neoplasms

NCT07272109 2025-12-15

PTCA199-16

210 enrolled

Pancreatic Neoplasms

NCT07262567 2025-12-03

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

320 enrolled

Pancreatic Neoplasms

NCT06177522 2025-11-18

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT07155629 2025-09-04

LEFT-PANC

381 enrolled

Pancreatic Cancer Resectable

NCT07151872 2025-09-03

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

120 enrolled

CLDN18.2-positive Advanced Biliary Tract Cancer

NCT07109167 2025-08-07

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

30 enrolled

Biliary Tract Neoplasms

NCT07028424 2025-07-01

PANORAMIX

206 enrolled

PDAC - Pancreatic Ductal Adenocarcinoma

NCT07030140 2025-06-22

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07003815 2025-06-04

Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer

62 enrolled

Phase 2/3 Not yet recruiting

Biliary Tract Neoplasms

NCT06923475 2025-04-11

NEODISCO

150 enrolled

Cholangiocarcinoma, Klatskin Tumor

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

60 enrolled

Phase 4 Not yet recruiting

Pancreatic Cancer Resectable

NCT06818773 2025-02-10

Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer

35 enrolled

Biliary Tract Neoplasms

NCT05562297 2025-01-22

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

50 enrolled

Pancreatic Neoplasms

NCT06274879 2025-01-09

Ablatio

36 enrolled

Bile Duct Neoplasms

NCT06662669 2024-10-29

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

120 enrolled

Pancreatic Neoplasms

NCT06621095 2024-10-01

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

104 enrolled

Pancreatic Neoplasms

NCT06591650 2024-09-19

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

GastrointestinalGenitourinary

33 enrolled

Gallbladder Cancer Unresectable

NCT06571461 2024-08-27

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

408 enrolled

Pancreatic Neoplasms

NCT06567600 2024-08-22

Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma

43 enrolled

Cholangiocarcinoma

NCT06513455 2024-07-22

Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer

132 enrolled

Pancreatic Neoplasms

NCT06233864 2024-04-17

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

63 enrolled

Pancreatic Neoplasms

NCT06370754 2024-04-17

FD-IMPACT

117 enrolled

Pancreatic Neoplasms

NCT06361030 2024-04-11

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

40 enrolled

Anophthalmia with pulmonary hypoplasia, Pancreatic Neoplasms

NCT06234072 2024-02-02

Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients

120 enrolled

Pancreatic Neoplasms

NCT06217042 2024-01-22

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

524 enrolled

Pancreatic Neoplasms

NCT05988372 2023-11-01

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

50 enrolled

Locally Advanced Pancreatic Cancer

NCT06080854 2023-10-12

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

108 enrolled

Phase NA Not yet recruiting

Pancreatic Neoplasms

NCT05903703 2023-06-15

Canagliflozin With Gemcitabine in Pancreatic Carcinoma

20 enrolled